Our patient might be affected by Mediterannean variant of G6PD deficiency, which is more sensitive to pro-oxidant drugs compared to African G6PD A variant. No conclusive data are available on the possible pro-hemolytic impact of CQ/HCQ on patient with G6PD deficiency [3–5]. In COVID-19 emergency we believe it is important to warning the possible hemolytic effects of CQ/HCQ in patients with G6PD deficiency. Thus, the acute drop in Hb levels in the early days of CQ/HCQ treatment of COVID19 symptomatic patient should be considered

Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury.

De Franceschi L
;
Dima F;Morandi M;Olivieri O.
2020-01-01

Abstract

Our patient might be affected by Mediterannean variant of G6PD deficiency, which is more sensitive to pro-oxidant drugs compared to African G6PD A variant. No conclusive data are available on the possible pro-hemolytic impact of CQ/HCQ on patient with G6PD deficiency [3–5]. In COVID-19 emergency we believe it is important to warning the possible hemolytic effects of CQ/HCQ in patients with G6PD deficiency. Thus, the acute drop in Hb levels in the early days of CQ/HCQ treatment of COVID19 symptomatic patient should be considered
2020
Covid-19, hydroxycloroquine, hemolysis
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0953620520301345-main-2.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 2.44 MB
Formato Adobe PDF
2.44 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1034956
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact